跳至主要内容
临床试验/NCT06262594
NCT06262594招募中3 期

Lemborexant Treatment of Insomnia Linked to Epilepsy

University of Manitoba2 个研究点 分布在 2 个国家目标入组 26 人开始时间: 2024年10月29日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
招募中
入组人数
26
试验地点
2
主要终点
WASO

研究概览

简要总结

The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Sleep-related focal epilepsy
  • Contraception

排除标准

  • Changes in antiseizure medication 1 month before study protocol or during study protocol
  • Concomitant medications per SUNRISE1
  • Individuals with hepatic impairment
  • Female participants who are pregnant or breastfeeding
  • Individuals with compromised respiratory function
  • Individuals with a history of complex sleep-related behaviour
  • Individuals with rare hereditary diseases of galactose intolerance such as galactosemia or glucose-galactose malabsorption
  • Individuals with a history of dependence or tolerance - abuse, dependence, rebound insomnia
  • Individuals with psychiatric disorders with abnormal thinking and behavioural changes, depression, or suicidal ideation
  • Individuals with a diagnosis of narcolepsy

研究组 & 干预措施

Placebo First

Placebo Comparator

0mg

干预措施: Lemborexant (Drug)

Placebo First

Placebo Comparator

0mg

干预措施: Placebo (Drug)

Investigational Product First

Active Comparator

10mg qhs

干预措施: Lemborexant (Drug)

Investigational Product First

Active Comparator

10mg qhs

干预措施: Placebo (Drug)

结局指标

主要结局

WASO

时间窗: 36 Days

Wake After Sleep Onset (recorded using PSG)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验